Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

180
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
180
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

143
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
143
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

244
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
244
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

240
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
240
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

334
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
334
Transmission-based Precautions II: Airborne and Protective Environment01:25

Transmission-based Precautions II: Airborne and Protective Environment

1.3K
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Versus Late(r) Administration of Intrapleural Fibrinolytic Therapy in Children with Empyema: A Systematic Review and Meta-Analysis.

Indian pediatrics·2026
Same author

Thoracic Computed Tomography Scan Versus Thoracic Ultrasonography for Management Decisions in Empyema Thoracis: A Systematic Review.

Indian pediatrics·2026
Same author

Clinical Profile of Cystic Fibrosis in India: A Multi-Centric Prospective Study.

Journal of paediatrics and child health·2026
Same author

Clinical Signs of Circulatory Impairment/Shock in Children: A Prospective Observational Study.

Indian journal of pediatrics·2026
Same author

Factors associated with pulmonary TB in malnourished children admitted to rehabilitation centres.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2026
Same author

Profile of cystic fibrosis transmembrane conductance regulator (CFTR) gene variants across India and their variability in different geographic regions.

Gene·2025

Related Experiment Video

Updated: Jul 8, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K

Tuberculosis Preventive Treatment.

Anshula Tayal1, S K Kabra2

  • 1Department of Pediatrics, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

Indian Journal of Pediatrics
|December 14, 2023
PubMed
Summary

TB preventive treatment (TPT) aims to prevent latent tuberculosis infection (LTBI) from progressing to active disease. Current TPT regimens include 6-month daily Isoniazid (6H) and a 3-month weekly Isoniazid/Rifapentine regimen (3HP).

Keywords:
Latent TB infectionTB infectionTB preventive treatment

More Related Videos

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.8K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K

Related Experiment Videos

Last Updated: Jul 8, 2025

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.8K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

18.8K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

7.9K

Area of Science:

  • Infectious Diseases
  • Public Health
  • Microbiology

Background:

  • Mycobacterium tuberculosis exposure can lead to latent TB infection (TBI), posing a lifelong risk of active disease.
  • TB preventive treatment (TPT) is crucial for managing TBI and preventing progression to active tuberculosis (TB).
  • Diagnosing TBI indirectly relies on immune-based tests like Tuberculin Skin Test (TST) and Interferon-Gamma Release Assays (IGRAs), as microbiological confirmation is not yet possible.

Purpose of the Study:

  • To review the evolution and current landscape of TB preventive treatment (TPT) regimens.
  • To highlight the importance of ruling out active TB before initiating TPT.
  • To discuss tailored TPT strategies for contacts of drug-resistant TB (DR-TB) cases and the need for monitoring.

Main Methods:

  • Review of existing TPT regimens, including 6-month daily Isoniazid (6H) and the emerging 3-month weekly Isoniazid and Rifapentine (3HP) regimen.
  • Discussion on diagnostic approaches for TBI using immune-based tests (TST, IGRAs).
  • Consideration of TPT for contacts of DR-TB patients, emphasizing resistance pattern analysis and bacteriological confirmation.

Main Results:

  • The 6H regimen is widely used, while 3HP is an emerging option for individuals over 2 years old.
  • Active TB must be excluded before starting TPT to ensure safety and efficacy.
  • TPT for DR-TB contacts requires specific regimens based on the index case's resistance profile.

Conclusions:

  • TPT is a vital strategy to combat tuberculosis by treating latent infection and preventing disease progression.
  • Close monitoring of individuals on TPT is essential to detect any signs of active TB promptly.
  • Advancements in TPT regimens and tailored approaches for specific populations, like DR-TB contacts, are critical for TB control efforts.